<DOC>
	<DOCNO>NCT00904098</DOCNO>
	<brief_summary>Females 18 year age old least one year history menstrual migraine ( MM ) headache participate Phase 4 clinical trial evaluate efficacy frovatriptan use early stage ( International Headache Society [ IHS ] Grade 1 ) MM compare patient ' current treatment .</brief_summary>
	<brief_title>Effectiveness And Safety Of Frovatriptan For The Management ( Acute Treatment ) Of Menstrual Migraine</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Premenstrual Syndrome</mesh_term>
	<mesh_term>Frovatriptan</mesh_term>
	<criteria>1 . Had MM headache occur Day −2 Day +3 menses 2 . Had least one year history MM headaches 3 . Had least 8 MM headache previous 12 menstrual cycle ( 1 year ) 4 . Had regular predictable menstrual period ( 28 ± 4 day ) 1 . Had history 15 headache day per month 2 . As part current MM treatment , use intermittent prevention analgesic ( e.g. , naproxen 5 day prevent onset MM ) 3 . Had history myocardial infarction , ischemic heart disease ( present symptom sign compatible ischemic heart disease ) , coronary vasospasm ( include Prinzmetal 's variant angina ) , significant underlie cardiovascular disease , peripheral vascular disease 4 . Had significant cerebrovascular disease , include basilar hemiplegic migraine 5 . Had uncontrolled hypertension : systolic blood pressure &gt; 180mmHg diastolic blood pressure &gt; 95mmHg 6 . Had severe hepatic renal insufficiency 7 . Used analgesic medication ( include prescription overthecounter ) reason &gt; 50 % day per month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>migraine</keyword>
</DOC>